Skip to content
Open in App
Immunovant logo

Immunovant

web2

Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the...

Symbol · IMVT
Company profile

About

Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases. It develops IMVT-1402, a human monoclonal antibody that inhibits neonatal fragment crystallizable receptor for graves' disease, rheumatoid arthritis, sjögren’s disease, cutaneous lupus erythematosus disease, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy. The company was founded in 2018 and is based in Durham, North Carolina. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.

Explore by sector

Explore this sector

Market identity

Exchange listings

Listing identities only. Orbitrum does not publish live prices or market performance on this public profile.

ExchangeNasdaqPrimary symbol: IMVT
Expert coverage

1 expert evaluated Immunovant.

Orbitrum research

Experts evaluating Immunovant

Explore the public profiles of experts who have evaluated this project.

Orbitrum Academy

Learn how to read a project assessment